<DOC>
	<DOCNO>NCT00693238</DOCNO>
	<brief_summary>The purpose trial give short course ( 5 ½ week ) radiation little side effect normal bladder rectal tissue usual long course ( 8 week ) radiation , without decrease chance kill prostate cancer cell .</brief_summary>
	<brief_title>Proton Therapy Low Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>Low Risk - Total 70 Gy/CGE 28 treatment Intermediate Risk - Total 72.5 Gy/CGE 29 treatment</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Prostate cancer . Gleason score 27 . PSA ≤ 20 ng/ml . Previous prostate cancer surgery pelvic radiation . Prior current chemotherapy prostate cancer . Active inflammatory bowel disease ( Crohn 's disease , diverticulitis ulcerative colitis ) affect rectum . History proximal urethral stricture require dilatation . History hip replacement . Diabetes require medication . Prior intrapelvic surgery . Current continue anticoagulation Warfarin sodium ( Coumadin ) , Clopidogrel bisulfate ( Plavix ) , enoxaparin sodium ( Lovenox ) , aspirin/er dipyridamole ( Aggrenox ) . On Flomax ( Tamsulosin ) , Hytrin ( Terazosin ) Cardura ( Doxazosin ) , Uroxatral ( alfuzosin HCl ) . Taking Saw Palmetto methotrexate unable unwilling discontinue use radiation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Proton Radiation</keyword>
</DOC>